These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 34922444)

  • 1. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
    J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
    Altamura C; Brunelli N; Marcosano M; Aurilia C; Egeo G; Lovati C; Favoni V; Perrotta A; Maestrini I; Schiano Di Cola F; d'Onofrio F; Finocchi C; Bertuzzo D; Bono F; Ranieri A; Albanese M; Messina R; Doretti A; Di Piero V; Cevoli S; Barbanti P; Vernieri F;
    J Neurol; 2022 Nov; 269(11):5848-5857. PubMed ID: 35763113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
    Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
    BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
    Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
    J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.
    Vernieri F; Brunelli N; Guerzoni S; Iannone LF; Baraldi C; Rao R; Schiano di Cola F; Ornello R; Cevoli S; Lovati C; Albanese M; Perrotta A; Cetta I; Rossi SS; Taranta V; Filippi M; Geppetti P; Sacco S; Altamura C
    J Neurol; 2023 Nov; 270(11):5436-5448. PubMed ID: 37468621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.
    Sirilertmekasakul C; Panto A; Lekhalawan P; Panyarachun P; Jindasakchai P; Rattanawong W
    Neurol Sci; 2024 Sep; 45(9):4451-4462. PubMed ID: 38564060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
    Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
    J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
    Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
    J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; D'Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
    J Neurol; 2024 May; 271(5):2434-2443. PubMed ID: 38231271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF; Yang FC; Chen LA; Chang TY; Su HC; Yang CP; Tu YH; Tzeng YS; Chen SP; Fuh JL; Lai KL; Ling YH; Chen WT; Wang SJ
    Eur J Neurol; 2024 Sep; 31(9):e16372. PubMed ID: 38837528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
    Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
    CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.